Skip to main content

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q3 '22

By: Newsfile
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Dallas, Texas--(Newsfile Corp. - December 19, 2022) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners updates coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH). The full report can be accessed by clicking on the following link: https://stonegateinc.com/reports/BPTH_Q322.pdf

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • Strong IP Position
  • Ongoing Clinical Trials
  • First Patients Recently Dosed

Cannot view this image? Visit: https://images.newsfilecorp.com/files/7294/148698_figure1_550.jpg

Click image above to view full announcement.


About Stonegate Capital Partners
Stonegate Capital Partners is a Dallas-based corporate advisory firm dedicated to serving the specialized needs of small-cap public companies. Since our inception, our mission has been to find innovative, undervalued public companies for our network of leading institutional investors who seek high-quality investment opportunities.

Contacts:

Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com

Source: Stonegate, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/148698

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  266.03
+15.34 (6.12%)
AAPL  349.51
+17.61 (5.31%)
AMD  488.78
+4.88 (1.01%)
BAC  51.63
+1.97 (3.97%)
GOOG  287.30
+9.03 (3.25%)
META  630.00
+8.97 (1.44%)
MSFT  555.80
+34.81 (6.68%)
NVDA  200.24
-6.45 (-3.12%)
ORCL  123.77
-2.42 (-1.92%)
TSLA  385.19
-13.31 (-3.34%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.